Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (full proposal, RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple awards possible; actual funding may be less than requested.
Summary: Supports independent educational initiatives to advance clinical decision-making and improve outcomes in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Only organizations (not individuals) may apply; proposals must be submitted via the Alnylam grant portal.